Hadar Duskin‐Bitan

659 total citations · 1 hit paper
26 papers, 430 citations indexed

About

Hadar Duskin‐Bitan is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Infectious Diseases. According to data from OpenAlex, Hadar Duskin‐Bitan has authored 26 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Surgery and 7 papers in Infectious Diseases. Recurrent topics in Hadar Duskin‐Bitan's work include Pituitary Gland Disorders and Treatments (11 papers), Growth Hormone and Insulin-like Growth Factors (10 papers) and Adrenal and Paraganglionic Tumors (7 papers). Hadar Duskin‐Bitan is often cited by papers focused on Pituitary Gland Disorders and Treatments (11 papers), Growth Hormone and Insulin-like Growth Factors (10 papers) and Adrenal and Paraganglionic Tumors (7 papers). Hadar Duskin‐Bitan collaborates with scholars based in Israel, United States and Russia. Hadar Duskin‐Bitan's co-authors include Ilan Shimon, Eyal Robenshtok, Talia Diker‐Cohen, Dania Hirsch, Amit Akirov, Gideon Bachar, Shlomit Yaron, Ronen Arbel, Elad Goldberg and Alon Peretz and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, The Lancet Infectious Diseases and Clinical Endocrinology.

In The Last Decade

Hadar Duskin‐Bitan

25 papers receiving 426 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study

2023 86 citations Ronen Arbel, Alon Peretz et al. The Lancet Infectious Diseases profile →

Peers

Countries citing papers authored by Hadar Duskin‐Bitan

Since Specialization

Citations

This map shows the geographic impact of Hadar Duskin‐Bitan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hadar Duskin‐Bitan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hadar Duskin‐Bitan more than expected).

Fields of papers citing papers by Hadar Duskin‐Bitan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hadar Duskin‐Bitan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hadar Duskin‐Bitan. The network helps show where Hadar Duskin‐Bitan may publish in the future.

Co-authorship network of co-authors of Hadar Duskin‐Bitan

This figure shows the co-authorship network connecting the top 25 collaborators of Hadar Duskin‐Bitan. A scholar is included among the top collaborators of Hadar Duskin‐Bitan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hadar Duskin‐Bitan. Hadar Duskin‐Bitan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study 2025 ·Endocrine ·(unknown), Nicolas Simon, (unknown), (unknown), (unknown), Hadar Duskin‐Bitan, Hiba Masri‐Iraqi, Gloria Tsvetov, Amit Akirov, Ilan Shimon	3
2	Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period 2025 ·Infectious Diseases and Therapy ·Samah Hayek, Joseph Levy, (unknown), Noa Dagan, (unknown), Hadar Duskin‐Bitan, Sabada Dube, Cátia Ferreira, (unknown), Carla Talarico, (unknown), Sudhir Venkatesan, (unknown), Ran D. Balicer, Doron Netzer, Alon Peretz	0
3	Increased cancer risk in a cohort of patients with acromegaly in Israel 2025 ·Endocrine Related Cancer ·Hadar Duskin‐Bitan, (unknown), Doron Netzer, Arnon D. Cohen, Doron Comaneshter, (unknown), Shlomit Yaron, (unknown), (unknown), (unknown), Ilan Shimon	1
4	Visual morbidity in macroprolactinoma: A retrospective cohort study 2024 ·Clinical Endocrinology ·(unknown), Hadar Duskin‐Bitan, Hiba Masri‐Iraqi, Amit Akirov, Ilan Shimon	1
5	Natural history of nonfunctioning pituitary macroadenomas followed without intervention: A retrospective cohort study 2023 ·Clinical Endocrinology ·(unknown), Eyal Robenshtok, Hadar Duskin‐Bitan, Gloria Tsvetov, Alexander Gorshtein, Amit Akirov, Ilan Shimon	5
6	Graves’ Disease Following COVID-19 Vaccination: A Population-based, Matched Case-control Study 2023 ·The Journal of Clinical Endocrinology & Metabolism ·Alexander Gorshtein, ‪Adi Turjeman‬‏, Hadar Duskin‐Bitan, Leonard Leibovici, Eyal Robenshtok	5
7	Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study 2023 ·The Lancet Infectious Diseases ·Dan Yamin, Matan Yechezkel, Ronen Arbel, (unknown), Ruslan Sergienko, Hadar Duskin‐Bitan, Shlomit Yaron, Alon Peretz, Doron Netzer, Erez Shmueli	19
8	Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men 2023 ·Andrology ·(unknown), Hadar Duskin‐Bitan, (unknown), Gloria Tsvetov, Hiba Masri‐Iraqi, Amit Akirov, Ilan Shimon	8
9	Long‐term response to cabergoline and multi‐modal treatment in men with macroprolactinoma: Does size really matter? 2021 ·Clinical Endocrinology ·(unknown), Hadar Duskin‐Bitan, Yossi Manisterski, Barak Pertzov, Amit Akirov, Hiba Masri‐Iraqi, Ilan Shimon	9
10	Polymicrobial and monomicrobial necrotizing soft tissue infections: comparison of clinical, laboratory, radiological, and pathological hallmarks and prognosis. A retrospective analysis 2021 ·Trauma Surgery & Acute Care Open ·(unknown), Shachaf Shiber, Hadar Duskin‐Bitan, Dafna Yahav, Jihad Bishara, Iftach Sagy, (unknown), Michael J. Drescher	10
11	True hyperprolactinemia in men without visible pituitary adenoma 2021 ·Endocrine ·Ilan Shimon, (unknown), Yossi Manisterski, Alexander Gorshtein, (unknown), Hadar Duskin‐Bitan	4
12	Benefits of a nurse-led home injection service for acromegaly patients treated with somatuline autogel 2020 ·Endocrine ·Amit Akirov, Hiba Masri‐Iraqi, Alexander Gorshtein, Hadar Duskin‐Bitan, (unknown), Ilan Shimon	2
13	Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required? 2020 ·Thyroid ·(unknown), Dania Hirsch, Hadar Duskin‐Bitan, (unknown), Ilan Shimon, Eyal Robenshtok	4
14	Hyperparathyroidism in patients over 75: Clinical characteristics and outcome. Is conservative treatment a safe alternative? 2020 ·Maturitas ·Hadar Duskin‐Bitan, (unknown), (unknown), Alexander Gorshtein, Hiba Masri‐Iraqi, Eyal Robenshtok, Talia Diker‐Cohen, Joelle Singer, Ilan Shimon, Dania Hirsch, Gloria Tsvetov	5
15	Bone-Marrow Suppression in Elderly Patients Following Empiric Radioiodine Therapy: Real-Life Data 2019 ·Thyroid ·Hadar Duskin‐Bitan, (unknown), (unknown), Talia Diker‐Cohen, Dania Hirsch, Carlos Benbassat, Ilan Shimon, Eyal Robenshtok	13
16	Prolactinomas in males: any differences? 2019 ·Pituitary ·Hadar Duskin‐Bitan, Ilan Shimon	35
17	Outcomes of hyperglycemia in patients with and without diabetes hospitalized for infectious diseases 2018 ·Diabetes/Metabolism Research and Reviews ·Amit Akirov, Talia Diker‐Cohen, Hiba Masri‐Iraqi, Hadar Duskin‐Bitan, Ilan Shimon, Alexander Gorshtein	9
18	Monomicrobial necrotizing fasciitis in a single center: the emergence of Gram-negative bacteria as a common pathogen 2014 ·International Journal of Infectious Diseases ·Dafna Yahav, Hadar Duskin‐Bitan, Noa Eliakim‐Raz, Haim Ben‐Zvi, Hila Shaked, Elad Goldberg, Jihad Bishara	33
19	The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort 2014 ·Clinical Rheumatology ·Hadar Duskin‐Bitan, Eytan Cohen, Elad Goldberg, Tzippy Shochat, Amos Levi, Moshe Garty, Ilan Krause	46
20	Kikuchi-Fujimoto disease 2011 ·SpringerReference ·Hadar Duskin‐Bitan, Shaye Kivity, David Olchovsky, Ginette Schiby, ‪David Ezra‬‏, Meir Mouallem	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact